Table 2.
Postoperative outcomes and complications in the included studies
| Authors and year | Pre op VAS/ post op VAS (lumbago or leg pain) | Pre op ODI (%)/post op ODI (%) | Recurrence | Reoperation | Residual cyst | Dural tear | Fusion | Operative time (mean ± SD, min) | blood loss (mean ± SD, ml) | Postoperative length of hospital stay (mean ± SD, days) | Follow-up (mean mos) | MacNab (excellent and good)/ Nurick(0–2) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Present series | 7/0.5 | 35.1 ± 6.3/0 | 0 | 0 | 0 | 0 | 0 | 197.5 ± 37.5 | 35 ± 15 | 6.5 ± 4.5 | 13.5 | 2/2 |
| Trummer, M., et al., 2001 | 1 | 1 | 0 | 0 | 0 | 5 | 22.7 | |||||
| Pirotte et al., 2003 | 4 | 0 | 0 | 0 | 1–132 | |||||||
| Sandhu, F.A., et al., 2004 | 1 | 1 | 0 | 97 (50–180) | 35 (5–100) | < 1 in 82% | 13 | 16/17 | ||||
| Khan, A.M., et al., 2005 | 1 | 4 | 2 | 26 | 231 (92–391) | 930 (200–2500) | 6.2 ± 3.4 | 26 | ||||
| Sehati, N., et al., 2006 | 0 | 0 | 0 | 2 | 0 | 158 (75–270) | 31 (10–100) | 1 in 68.4% | 16 | 18/19 | ||
| James, A., et al., 2012 | 7.6/0.6 | 0 | 0 | 2 | 0 | 105 ± 37 | < 40 | 18 | 14/14 | |||
| Landi et al., 2012 | 0 | 1 | 0 | 0 | 24 | |||||||
| Jankowski et al., 2012 | 0 | 0 | 0 | 0 | 12 | |||||||
| Rhee, J., et al., 2012 | 0 | 0 | 0 | 0 | 0 | 74 ± 1.41 | 27.5 | 0.6 ± 0.73 | 12 | 2/2 | ||
| Komp, M., et al., 2014 | 7.6/2.2 | 2 | 2 | 2 | 22 (14–43) | No measurable | 24 | 71/74 | ||||
| Zhenbo, Z., et al., 2014 | 7.5 ± 1.7/2.5 ± 0.8 | 0 | 0 | 4 | 71.7 ± 5 | 144.1 ± 10.7 | 58.8 | |||||
| Knafo, S., et al., 2015(1) | 2 | 2 | 12/18 | |||||||||
| Knafo, S., et al., 2015(2) | 0 | 0 | 2/3 | |||||||||
| Scholz, C., et al.,2015(1) | 0 | 0 | 95.5 | |||||||||
| Scholz, C., et al., 2015(2) | 0 | 0 | 36 | |||||||||
| Sukkarieh, H. G., et al., 2015 | 7.8/2.9 | 0 | 0 | 1 | 0 | 123 ± 30 | 44 | 1.5 ± 0.7 | 20.8 | 10/13 | ||
| Klessinger, 2016 | 0 | 1 | 0 | 5 | 0 | 4.2 | 29/38 | |||||
| Birch, B.D., et al., 2016 | 1 | 2 | 2 | 58 ± 18.7 | 20 | 0.17 ± 0.07 | 79 | 37/40 | ||||
| Denis, D.R., et al., 2016 | 1 | 2 | 2 | 181.96 ± 3283 | 42.5 | 0.28 ± 0.68 | 14.8 | 34/40 | ||||
| Krzok, G., et al., 2016 | 1 | |||||||||||
| Kulkarni et al., 2017 | 7.6 ± 0.9/1.6 ± 1.04 | 61.50 ± 8.4/13.16 ± 5.14 | 0 | 0 | 0 | 1 | 0 | 46.5 | 30/30 | |||
| Bruder, M., et al., 2017 | 8 | 7 | 8 | 0 | 111 | 76/81 | ||||||
| Domenicucci, M., et al., 2017 | 7.4/1.3 | 0 | 1 | 0 | 2 | 12 | 28.5 | |||||
| Hwang, J.H., et al., 2017 | 6/2 | 54.83 ± 7.13/27.43 ± 1.27 | 0 | 0 | 55 | 6 | 3/3 | |||||
| Lista- Martínez, O., et al., 2017 | 0 | 1 | 0 | 7 | 12 | 6/9 | ||||||
| Oertel, J.M, et al., 2017 | 1 | 4 | 0 | 59 (41–75) | 10.5 | 9/11 | ||||||
| Vergara, P., et al., 2017(1) | /4.7 | 0 | 1 | 1 | 109 ± 37 | 1.5 ± 0.57 | 14.9 | |||||
| Vergara, P., et al., 2017(2) | /0.9 | 0 | 0 | 1 | 103 ± 27 | 0.63 ± 0.3 | 9.4 | |||||
| Bruder, M., et al., 2018 | 8 | 9 | 8 | 73.3 | 108/124 | |||||||
| Akbary, K., et al., 2019 | 65.08 ± 7.95/13.46 ± 5.19 | 0 | 0 | 62.31 ± 14.23 | < 50 | |||||||
| Heo, D.H., et al., 2019 | 7.64 ± 0.71/1.63 ± 1.28 | 45.35 ± 16.15/15.82 ± 10.21 | 0 | 0 | 0 | 0 | 60.1 ± 23.4 | 10.1 | ||||
| Landriel, F., et al., 2019 | 8.3/2.5 | 0 | 0 | 1 | 5 | 150.33 ± 6331 | 2.5 ± 1.78 | 26 | 19/19 | |||
| Rahim, T., et al., 2019 | 4 | 5 | 104.4 | 240/283 | ||||||||
| Telfeian, A.E., et al., 2019 | 7/2 | 28 ± 2.8/5 ± 1.41 | 0 | 0 | 0 | 24 | 2/2 | |||||
| Wu, H.H., et al., 2019 | 7.75/0.63 | 0 | 0 | 0 | 0 | 75.75 + 16.3 | Minimal | 1.25 ± 0.46 | 12 | 7/7 | ||
| Rosenstock T., et al., 2020 | 7 | 23 | 0 | 3 | 16 | 2.25 | ||||||
| Rolemberg Dantas, F.L.,et a.,2020 | 0 | 3 | 0 | 3 | 0 | 2.18 ± 0.6 | 87.6 | 47/50 | ||||
| Tacconi, L., et al., 2020 | 6.8/2.1 | 2 | 4 | 2 | 2 | 0 | 78 (36–150) | 15 | 27/35 | |||
| Hellinger, S., et al., 2020 | 8.07 ± 1.57/1.67 ± 1.32 | 0 | 2 | 0 | 0 | 0 | Minimal | 55.46 | 37/47 | |||
| Page et al., 2021 | 11 | 0 | 0 | 85 | 77/85 | |||||||
| Soriano Sánchez, J.A., et al., 2021 | 8.24/2.21 | 41.02 ± 12.58/11.82 ± 10.52 | 1 | 3 | 13 | 143 (55–360) | 2(1–5) | 17 | 272/33 | |||
| Lalanne, L. B., et al., 2022 | 1 | 0 | 2 | 69 | 94.8 | 63/69 | ||||||
| Chesney, K., et al., 2022 | 1 | 17 | 0 | 1 | 0 | 94 (46–183) | 22 (5–100) | < 2 in 92% | 46 | 63/81 | ||
| Francavilla TL., et al., 2022 | 6.2 ± 2.3/3.1 ± 2.8 | 46.7 ± 13.5/24.7 ± 19 | 0 | 0 | 0 | 0 | 0 | 72 + 35 | 52 ± 101 | 0.085 | 4.17 |